Literature DB >> 19379927

Obliteration of empyema space by vascularized anterolateral thigh flaps.

Masaya Okuda1, Hiroyasu Yokomise, Gan Muneuchi, Shinya Ishikawa.   

Abstract

Closure of the fistula and an appropriate choice of obliterating agents are crucial for the treatment of empyema with bronchopleural fistula. The choice of the material to be used for obliteration of the pleural space is a difficult one in some patients, such as those with empyema, developing after omentectomy, laparotomy, posterolateral thoracotomy, and so forth. The use of free anterolateral thigh flaps for obliteration of the pleural space generally needs a satisfactory vascular network around the thorax. We report two successfully treated cases of empyema with bronchial fistula, which were otherwise difficult to manage, in which a free anterolateral thigh musculocutaneous flap anastomosed to the superior thyroid vessels used to obliterate the pleural space.

Entities:  

Mesh:

Year:  2009        PMID: 19379927     DOI: 10.1016/j.athoracsur.2008.09.006

Source DB:  PubMed          Journal:  Ann Thorac Surg        ISSN: 0003-4975            Impact factor:   4.330


  3 in total

1.  Indications and Results of Reconstructive Techniques with Flaps Transposition in Patients Requiring Complex Thoracic Surgery: A 12-Year Experience.

Authors:  Sonia Gaucher; Filippo Lococo; Claude Guinet; Antonio Bobbio; Pierre Magdeleinat; Samir Bouam; Jean-François Regnard; Marco Alifano
Journal:  Lung       Date:  2016-07-09       Impact factor: 2.584

2.  Free musculocutaneous flap transfer for refractory chronic empyema with chest wall sinus in a 43-year-old male with hemophilia A.

Authors:  Xiaowen He; Zhongliang He; Lifeng Shen; Guoxing Chen; Xueming He
Journal:  J Thorac Dis       Date:  2018-06       Impact factor: 2.895

3.  Free vastus lateralis musculocutaneous flap transfer for radiation-induced chest wall fistula combined with osteomyelitis: Two case report.

Authors:  Xia Hong; Zhongliang He; Lifeng Shen; Xueming He
Journal:  Medicine (Baltimore)       Date:  2019-05       Impact factor: 1.817

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.